Elevance Health, Inc. (NYSE:ELV - Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $543.13 and last traded at $541.54, with a volume of 199794 shares changing hands. The stock had previously closed at $538.58.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. Barclays boosted their price target on Elevance Health from $584.00 to $621.00 and gave the stock an "overweight" rating in a research note on Friday, April 19th. Truist Financial reissued a "buy" rating and set a $600.00 price target (up previously from $580.00) on shares of Elevance Health in a research note on Friday, April 19th. UBS Group boosted their price target on Elevance Health from $585.00 to $605.00 and gave the stock a "buy" rating in a research note on Friday, April 19th. Wells Fargo & Company upped their target price on Elevance Health from $557.00 to $600.00 and gave the company an "overweight" rating in a research note on Friday, April 19th. Finally, Mizuho upped their target price on Elevance Health from $575.00 to $585.00 and gave the company a "buy" rating in a research note on Wednesday, April 24th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Elevance Health currently has an average rating of "Moderate Buy" and an average target price of $587.42.
View Our Latest Stock Analysis on ELV
Elevance Health Trading Up 0.1 %
The firm has a fifty day moving average of $515.92 and a 200 day moving average of $490.89. The firm has a market capitalization of $125.27 billion, a PE ratio of 20.41, a P/E/G ratio of 1.16 and a beta of 0.79. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.37 and a current ratio of 1.37.
Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, beating analysts' consensus estimates of $10.54 by $0.10. The business had revenue of $42.27 billion during the quarter, compared to analyst estimates of $42.49 billion. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The business's revenue was up .9% on a year-over-year basis. During the same period last year, the business earned $9.46 EPS. Equities research analysts expect that Elevance Health, Inc. will post 37.26 EPS for the current year.
Elevance Health Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 25th. Stockholders of record on Monday, June 10th will be given a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.21%. The ex-dividend date is Monday, June 10th. Elevance Health's payout ratio is currently 24.64%.
Insider Activity at Elevance Health
In other Elevance Health news, EVP Felicia F. Norwood sold 14,111 shares of the business's stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the completion of the sale, the executive vice president now owns 31,460 shares in the company, valued at $16,791,460.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.29% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in ELV. OFI Invest Asset Management acquired a new position in Elevance Health during the 3rd quarter worth $25,000. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Elevance Health in the fourth quarter valued at $28,000. Palisade Asset Management LLC acquired a new stake in shares of Elevance Health in the first quarter valued at $28,000. Alaska Permanent Fund Corp acquired a new stake in shares of Elevance Health in the fourth quarter valued at $31,000. Finally, Beaird Harris Wealth Management LLC acquired a new stake in shares of Elevance Health during the fourth quarter worth $32,000. 89.24% of the stock is currently owned by institutional investors.
Elevance Health Company Profile
(
Get Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
